ICU Medical (ICUI) AI Stock Analysis

• Market Cap: $3.10B
• Dividend Yield: N/A
• Average Volume (3M): 270.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: -0.81%
• EPS Growth: 93.27%
• Country: US
• Employees: 15,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 2.03
• Shares Outstanding: 24,685,715
• 10 Day Avg. Volume: 234,095
• 30 Day Avg. Volume: 270,295
• PEG Ratio: -0.11
• Price to Book (P/B): 1.93
• Price to Sales (P/S): 1.59
• P/FCF Ratio: 30.36
• Enterprise Value/Market Cap: 1.41
• Enterprise Value/Revenue: 1.88
• Enterprise Value/Gross Profit: 5.16
• Enterprise Value/Ebitda: 13.48
• 1Y Price Target: $173.50
• Price Target Upside: 20.45% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: $154.00 ▲(6.91% Upside)

ICU Medical's overall stock score is driven by a positive earnings call and strong technical indicators, which are offset by financial performance challenges and a concerning valuation. The company's operational improvements and increased guidance are significant strengths, but profitability issues and a negative P/E ratio present risks.

Positive Factors

Revenue Growth

The company demonstrates strong revenue growth, indicating robust demand for its products and effective market strategies, which can drive long-term success.

Product Innovation

Ongoing product innovation and FDA engagement suggest a commitment to expanding and enhancing the product portfolio, supporting future growth and competitive positioning.

Debt Management

Effective debt management and improved cash flow enhance financial stability, providing flexibility for strategic investments and reducing financial risk.

Negative Factors

Profitability Challenges

Ongoing profitability issues, such as a negative net profit margin, may hinder the company's ability to reinvest in growth and could affect long-term financial health.

Tariff Impact

Tariff-related expenses are expected to increase, potentially impacting cost structures and profitability, posing a risk to financial performance.

Segment Decline

Significant decline in the Vital Care segment indicates potential market challenges or product issues, which could affect overall revenue and market position.

ICU Medical Business Overview & Revenue Model

Company Description

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

How the Company Makes Money

ICU Medical generates revenue primarily through the sale of its medical devices and products, specifically in the infusion therapy market. Key revenue streams include the direct sales of infusion pumps, IV sets, and related accessories to hospitals and healthcare institutions globally. The company also earns income through recurring sales of consumables associated with its devices. Significant partnerships with healthcare providers and distributors enhance its market reach and sales potential. Additionally, ICU Medical has benefited from strategic acquisitions that bolster its product portfolio and expand its market presence, contributing to overall revenue growth.

ICU Medical Financial Statement Overview

Summary

ICU Medical's financial performance is mixed. The income statement shows declining revenue and profitability, but there are improvements in leverage and cash flow generation. The company needs to focus on reversing revenue declines and enhancing profitability for better financial health.

Income Statement

ICU Medical's income statement shows a mixed performance. The company has experienced a decline in revenue growth, with a negative growth rate of -2.20% in the TTM period. Profitability metrics are also concerning, with a negative net profit margin of -0.25% and a low EBIT margin of 3.42%. However, the gross profit margin remains relatively stable at 36.47%, indicating some operational efficiency. The company needs to address its declining revenue and improve profitability to enhance its financial health.

Balance Sheet

The balance sheet reflects moderate financial stability. The debt-to-equity ratio has improved to 0.62 in the TTM period, indicating a reduction in leverage compared to previous years. However, the return on equity remains negative at -0.28%, suggesting challenges in generating returns for shareholders. The equity ratio is not explicitly provided, but the company appears to maintain a reasonable level of equity relative to its assets. Continued focus on reducing debt and improving profitability is essential for long-term stability.

Cash Flow

ICU Medical's cash flow statement shows some positive trends. The free cash flow has grown by 13.74% in the TTM period, indicating improved cash generation capabilities. The operating cash flow to net income ratio is 0.32, suggesting that the company is generating cash from operations, albeit at a modest level. The free cash flow to net income ratio is 0.44, reflecting a reasonable conversion of earnings to cash. While there are improvements, further enhancement in cash flow generation is needed to support growth and reduce financial risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.32B	2.38B	2.26B	2.28B	1.32B	1.27B
Gross Profit	846.31M	824.78M	739.87M	697.76M	491.49M	461.50M
EBITDA	324.18M	42.96M	253.20M	191.55M	223.46M	194.09M
Net Income	-7.36M	-117.69M	-29.66M	-74.29M	103.14M	86.87M
Balance Sheet
Total Assets	4.10B	4.20B	4.38B	4.52B	1.88B	1.76B
Cash, Cash Equivalents and Short-Term Investments	299.73M	308.57M	254.72M	213.01M	567.25M	410.78M
Total Debt	1.36B	1.64B	1.70B	1.73B	45.05M	52.70M
Total Liabilities	1.98B	2.24B	2.26B	2.43B	264.71M	261.43M
Stockholders Equity	2.13B	1.97B	2.12B	2.09B	1.62B	1.50B
Cash Flow
Free Cash Flow	67.14M	124.66M	72.53M	-161.46M	186.37M	122.36M
Operating Cash Flow	159.44M	204.03M	166.20M	-62.13M	267.54M	222.75M
Investing Cash Flow	114.07M	-88.96M	-87.95M	-1.91B	-90.69M	-98.14M
Financing Cash Flow	-285.23M	-55.80M	-35.98M	1.64B	-16.87M	-40.00K

ICU Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 144.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ICUI, the sentiment is Positive. The current price of 144.04 is above the 20-day moving average (MA) of 140.33, above the 50-day MA of 128.03, and above the 200-day MA of 132.92, indicating a bullish trend. The MACD of 5.55 indicates Negative momentum. The RSI at 59.83 is Neutral, neither overbought nor oversold. The STOCH value of 63.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ICUI.

ICU Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COO	75 Outperform	$15.08B	37.34	5.01%	―	6.35%	12.94%
HOLX	69 Neutral	$16.68B	30.13	11.12%	―	1.74%	-25.29%
BDX	64 Neutral	$54.36B	32.75	6.54%	2.35%	8.23%	-2.04%
ICUI	61 Neutral	$3.10B	-82.51	-0.35%	―	-0.81%	93.27%
ATR	60 Neutral	$7.98B	19.49	15.80%	1.48%	2.50%	25.05%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAX	40 Neutral	$9.68B	―	-4.70%	2.76%	-21.20%	-325.40%

ICU Medical Corporate Events

ICU Medical’s Earnings Call Highlights Growth and Challenges

ICU Medical’s recent earnings call presented a predominantly positive sentiment, highlighting significant revenue growth and improved earnings. The company has increased its guidance, reflecting confidence in its future performance. Despite facing challenges such as tariff impacts and segment declines, the overall outlook remains optimistic, with the highlights outweighing the lowlights.

ICU Medical Reports Q3 2025 Earnings and Updates Guidance

ICU Medical, Inc. is a global leader in the development and sale of infusion systems, consumables, and critical care products, catering to hospital and home care settings. Headquartered in San Clemente, California, the company is known for its focus on quality and innovation in the medical products sector.

ICU Medical’s Earnings Call: Stability Amid Tariff Challenges

The latest earnings call from ICU Medical presented a balanced sentiment, highlighting stable revenue performance alongside notable growth in consumables and IV systems. However, the company faces significant challenges due to increased tariffs impacting profitability, prompting adjusted guidance. Despite these hurdles, ICU Medical remains committed to mitigating these impacts while continuing to invest in innovation and infrastructure improvements.

ICU Medical Reports Improved Profitability in Q2 2025

ICU Medical, Inc. is a global leader in the development, manufacture, and sale of innovative medical products, primarily focusing on infusion systems, infusion consumables, and critical care products for hospital and home care settings. Headquartered in San Clemente, California, the company is known for its commitment to quality, innovation, and value.